Biowaiver monographs for immediate release solid oral dosage forms: lamivudine

Area of Science:

• Pharmaceutical Sciences
• Drug Development
• Regulatory Science

Background:

• Lamivudine is an antiretroviral medication used in treating HIV/AIDS.
• Immediate-release solid oral dosage forms are common for lamivudine administration.
• Bioequivalence (BE) testing is crucial for generic drug approval, but waivers can expedite the process.

Purpose of the Study:

• To review literature data supporting a waiver of in vivo bioequivalence testing for lamivudine immediate-release solid oral dosage forms.
• To evaluate lamivudine's physicochemical and pharmacokinetic properties for Biopharmaceutics Classification System (BCS) assignment.
• To establish criteria for recommending biowaivers for lamivudine multisource products.

Main Methods:

• Literature review of lamivudine's solubility, permeability, therapeutic index, pharmacokinetics, and excipient interactions.
• Analysis of reported bioavailability (BA) and bioequivalence (BE) studies.
• Classification of lamivudine within the Biopharmaceutics Classification System (BCS).

Main Results:

• Lamivudine is highly soluble with bioavailability ranging from 82% to 88%, placing it in BCS Class III (near BCS Class I).
• Lamivudine is not considered a narrow therapeutic index drug.
• A biowaiver is recommended for new lamivudine IR products and post-approval changes if specific excipient and dissolution criteria are met.

Conclusions:

• Lamivudine's properties support the potential for biowaivers under defined conditions.
• Meeting BCS dissolution criteria and using approved excipients are key for waiving in vivo BE testing.
• Biowaivers can streamline the approval of generic lamivudine products and facilitate post-approval modifications.